Related by context. All words. (Click for frequent words.) 77 postoperative chemotherapy 77 adjuvant radiotherapy 76 preoperative chemotherapy 74 neoadjuvant therapy 73 neoadjuvant chemotherapy 73 chemoradiation 73 neoadjuvant 73 adjuvant therapy 72 chemoradiotherapy 72 debulking surgery 72 chemoradiation therapy 71 cytoreductive surgery 71 adjuvant chemotherapy 71 EBRT 71 postoperative radiotherapy 71 Doxil ® 70 external beam radiotherapy 70 oral clodronate 70 cystectomy 70 locoregional recurrence 70 ALND 69 axillary dissection 69 FOLFOX4 69 androgen deprivation 69 curative resection 69 axillary node dissection 69 lymphadenectomy 69 cytoreduction 69 Adjuvant chemotherapy 69 recurrent NSCLC 69 adjuvant therapies 68 metastatic RCC 68 pCR 68 liver metastases 68 sentinel lymph node biopsy 68 colorectal liver metastases 68 biochemical relapse 68 tumor resection 68 chemoembolization 68 contralateral breast 68 radiotherapy RT 68 concurrent chemoradiation 67 locoregional 67 fallopian tube carcinoma 67 EUS FNA 67 clinically localized prostate 67 carboplatin paclitaxel 67 ALA PDT 67 nephron sparing surgery 67 radical nephrectomy 67 recurrent metastatic 67 Zevalin consolidation 67 gemcitabine chemotherapy 67 neoadjuvant treatment 67 GnRH agonists 67 mycophenolate mofetil 67 ABVD 67 renal tumors 67 operable breast cancer 67 standard chemotherapy regimens 67 SLNB 67 allogeneic stem cell 67 surgical debulking 67 cisplatin chemotherapy 67 tumor recurrence 67 peritoneal cancer 67 sentinel node biopsy 66 distant metastases 66 dose cytarabine 66 FOLFOX6 66 Radical prostatectomy 66 adecatumumab 66 Ceplene/IL-2 66 nonmetastatic 66 chemotherapy cisplatin 66 liver metastasis 66 recurrent glioblastoma multiforme 66 unresectable tumors 66 pancreatic adenocarcinoma 66 breast conserving 66 #Gy 66 androgen suppression 66 5-fluorouracil/leucovorin 66 relapsed ovarian cancer 66 resectable 66 recurrent prostate cancer 66 transurethral resection 66 hepatic metastases 65 endometrial hyperplasia 65 hormonal therapy 65 radical cystectomy 65 thoracoscopic lobectomy 65 hypofractionated 65 postoperative morbidity 65 metastatic renal cell carcinoma 65 metastatic GIST 65 Platinol ® cisplatin 65 advanced adenomas 65 nephrectomy 65 abdominal hysterectomy 65 stage IIIB 65 medically inoperable 65 NMIBC 65 orchiectomy 65 radiochemotherapy 65 liver resection 65 IV NSCLC 65 brain metastases 65 stage IIIb IV 65 lymph node involvement 65 underwent resection 65 allogeneic SCT 65 pegylated liposomal doxorubicin 65 Accelerated Partial Breast Irradiation 65 axillary node 65 salpingo oophorectomy 65 non squamous NSCLC 65 intravenous bisphosphonates 65 fallopian tube cancers 65 nab paclitaxel 65 bilateral orchiectomy 65 anthracycline taxane 65 peritoneal carcinomatosis 65 paclitaxel carboplatin 65 TTF Therapy 65 axillary nodes 65 Surgical resection 65 lymph node dissection 65 5-FU/LV 65 cranial radiation 65 paclitaxel eluting stents 65 prostate carcinoma 64 mCRC patients 64 MAGE A3 ASCI 64 pelvic lymphadenectomy 64 sorafenib Nexavar 64 docetaxel chemotherapy 64 antitumor effect 64 patients undergoing CABG 64 lymph node removal 64 PSA nadir 64 adjuvant tamoxifen 64 antithrombotic therapy 64 metastatic lung cancer 64 unresectable 64 invasive coronary angiography 64 Neoadjuvant 64 perioperative morbidity 64 HBeAg seroconversion 64 nodal metastases 64 HER2 positive metastatic breast 64 PSADT 64 resected pancreatic cancer 64 adenoma recurrence 64 metastatic gastric 64 prostate cancer CRPC 64 HNSCC 64 platinum refractory 64 CYPHER Stent 64 KRAS mutations occur 64 decompressive surgery 64 percutaneous cryoablation 64 XELOX 64 complete cytogenetic response 64 MGd 64 oophorectomy 64 metastatic castration resistant 64 postoperative mortality 64 renal cell carcinomas 64 preoperative radiotherapy 64 invasive lobular carcinoma 64 total thyroidectomy 64 relapsed SCLC 64 interferon ribavirin 64 gemcitabine Gemzar 64 everolimus eluting stents 64 carotid stenosis 64 mitomycin C 64 nonoperative 64 chemotherapy docetaxel 64 HER2 negative 64 anthracycline containing 64 sentinel node 64 FOLPI 64 hepatectomy 64 Pegylated Interferon 64 seminoma 64 recurrent GBM 64 MRgFUS 64 metastatic HRPC 64 radiation therapy SBRT 64 surgical excision 64 tamoxifen therapy 64 skeletal metastases 64 hepatic resection 64 adjuvant systemic 64 unresectable stage 64 relapsed MM 64 KRAS mutation 64 sustained virological response 64 CR nPR 63 pT2 63 Gliadel Wafer 63 plus dexamethasone 63 revascularization procedures 63 trastuzumab 63 adjuvant cisplatin 63 noninvasive outpatient 63 radiofrequency ablation RFA 63 methotrexate monotherapy 63 LHRH receptor positive 63 allogeneic hematopoietic stem cell 63 TURP 63 CIMZIA ™ 63 irinotecan chemotherapy 63 thyroid nodules 63 antiangiogenic therapy 63 axillary lymph nodes 63 lumbar disk herniation 63 axillary lymph node dissection 63 intraperitoneal chemotherapy 63 5FU 63 oral Xeloda 63 pneumonectomy 63 flutamide 63 Thal Dex 63 evaluating tivozanib 63 basal cell carcinoma BCC 63 R0 resection 63 biochemical recurrence 63 radioiodine therapy 63 STRIDE PD 63 clodronate 63 chemoresistant 63 malignant pleural mesothelioma 63 HoLEP 63 epithelial ovarian cancer 63 paclitaxel cisplatin 63 morphometric vertebral fractures 63 pegylated interferon alfa 2b 63 esophagectomy 63 trastuzumab Herceptin ® 63 HER2 positive cancers 63 IORT 63 metastatic colorectal 63 radical prostatectomy 63 underwent surgical resection 63 intravesical therapy 63 hormone deprivation 63 tumor excision 63 thromboprophylaxis 63 ipsilateral breast 63 severe neutropenia 63 placebo dexamethasone 63 SCCHN 63 F FDG PET 63 bevacizumab Avastin ® 63 gemcitabine carboplatin 63 lung metastases 63 localized renal 63 oral ridaforolimus 63 mRCC 63 radiation chemoradiation 63 antioxidant supplementation 63 interferon alfa 2a 63 lenalidomide Revlimid R 63 conventional angiography 63 advanced adenoma 63 partial nephrectomy 63 cytotoxic therapy 63 iniparib 63 baseline LDH 63 minimally symptomatic 63 palliative radiotherapy 63 TORISEL 63 urine cytology 63 metastatic CRC 63 androgen suppression therapy 63 dacarbazine 63 HGPIN 63 parathyroidectomy 63 KRAS status 63 cytoreductive nephrectomy 63 completely resected 63 EBUS FNA 63 virological response 63 Xelox 63 vaginal hysterectomy 63 endometrial carcinoma 63 HSCT 63 antimicrobial prophylaxis 63 folinic acid 63 adriamycin 63 beam radiotherapy 63 breast endometrial 63 goserelin 63 locoregional disease 63 lipid lowering therapy 63 moderate renal impairment 62 dacarbazine DTIC 62 EGFR TKI 62 histologically proven 62 prostate cancer CaP 62 bevacizumab Avastin Genentech 62 biliary tract cancer 62 node dissection 62 sustained virologic response 62 breast conserving lumpectomy 62 metastatic bone 62 HER2 expression 62 bilateral oophorectomy 62 urothelial carcinoma 62 cystoscopic 62 perioperative complications 62 colorectal cancer liver metastases 62 TAXOTERE R 62 CTAP# Capsules 62 advanced hepatocellular carcinoma 62 Capecitabine 62 repigmentation 62 PSMA ADC 62 TroVax ® 62 rFVIIa 62 Pegasys plus Copegus 62 recurrent ovarian cancer 62 adjuvant hormonal therapy 62 recurrent malignant glioma 62 mammographic density 62 superficial bladder cancer 62 endometrial biopsy 62 vandetanib 62 riociguat 62 FOLFOX 62 dacarbazine chemotherapy 62 taxane therapy 62 colectomy 62 IV bisphosphonates 62 perioperative mortality 62 HER2 overexpression 62 chemo radiotherapy 62 FDG-PET/CT 62 Mammosite 62 excisional biopsy 62 palifermin 62 TNF alpha antagonist 62 lymph node metastases 62 percutaneous biopsy 62 localized prostate 62 HER2 positive tumors 62 temsirolimus 62 hormone receptor negative 62 core needle biopsy 62 papillary renal cell carcinoma 62 ICD implantation 62 TACE 62 thrombotic complications 62 pT3 62 MAL PDT 62 heavily pretreated patients 62 Chemoradiation 62 precursor lesions 62 ELACYT 62 metastatic castrate resistant 62 endarterectomy 62 metastatic pancreatic 62 palliation 62 #F FDG PET 62 SLN biopsy 62 Taxotere ® 62 platelet reactivity 62 asymptomatic carotid stenosis 62 plus prednisone 62 recurrent ovarian 62 paclitaxel Taxol R 62 transplantation HCT 62 balloon brachytherapy 62 fine needle aspiration 62 comparator arm 62 metastatic malignant 62 BRCA1 mutation carriers 62 pamidronate 62 resectable pancreatic cancer 62 epirubicin 62 ACTEMRA TM 62 pelvic radiotherapy 62 Metastatic Prostate Cancer 62 intraperitoneal therapy 62 sentinel lymph node 62 Mitomycin C 62 squamous histology 62 autologous chondrocyte implantation 62 ZOLINZA 62 epithelial tumors 62 allogeneic HSCT 62 invasive aspergillosis 62 axillary lymph node 62 endoscopic resection 62 beta blocker therapy 62 Torisel 62 Castration Resistant Prostate Cancer 62 radical prostatectomy RP 62 grade cervical intraepithelial 62 Pemetrexed 62 Recurrence Score 62 nonoperative treatment 62 endosonography 62 corticosteroid therapy 62 HIPEC 62 endocrine therapies 62 cisplatin vinorelbine 62 Metastatic Colorectal Cancer 62 definite stent thrombosis 62 infusional 62 Natalizumab 62 transarterial chemoembolization 62 haematologic 62 NATRECOR ® 62 smoldering multiple myeloma 62 infusional 5-FU/LV 62 Bevacizumab Avastin 62 catheter angiography 62 breast carcinoma 62 metastatic bladder 62 BEXXAR Therapeutic Regimen 62 Renal Cell Carcinoma RCC 62 ovarian carcinoma 62 Bezielle 62 aromatase inhibitor therapy 62 resistant hormone refractory 62 elective PCI 62 antibiotic prophylaxis 62 vincristine doxorubicin 62 BRCA2 mutation carriers 62 FOLFIRI 62 zalutumumab 62 pancreatic lung 62 extrapleural pneumonectomy 62 PROSTVAC VF 61 CMV disease 61 lenalidomide dexamethasone 61 variceal hemorrhage 61 subtrochanteric 61 remission CR 61 lumbar spine BMD 61 Sentinel Lymph Node Biopsy 61 Hepatocellular Carcinoma HCC 61 nonpharmacologic 61 pelvic malignancies 61 resected 61 T1c 61 radiation therapy 61 APTIVUS r 61 nonischemic 61 histologically confirmed 61 neoadjuvant chemoradiotherapy 61 invasive carcinoma 61 atypical hyperplasia 61 colorectal adenoma 61 cisplatin gemcitabine 61 nonsmall cell lung cancer 61 antithymocyte globulin 61 transabdominal 61 ER CHOP 61 tumor histology 61 BENICAR HCT 61 docetaxel Taxotere ® 61 micrometastases 61 immunosuppressive medication 61 bevacizumab Avastin 61 virologic responses 61 nonmetastatic prostate cancer 61 Endometrial 61 postoperative complication 61 HRPC 61 pediatric malignancies 61 CYT# potent vascular disrupting 61 perioperatively 61 cisplatin 61 adenomatous polyps 61 BEACOPP 61 oncologic outcomes 61 PASI scores 61 myeloablative 61 metastatic disease 61 relapsing remitting MS RRMS 61 prostate TURP 61 breast irradiation 61 adrenalectomy 61 graft occlusion 61 endometrial cancers 61 5 FU leucovorin 61 infliximab monotherapy 61 stereotactic radiotherapy 61 ductal cancer 61 doxorubicin HCl liposome injection 61 metastatic colorectal carcinoma 61 octreotide LAR 61 ovarian suppression 61 ixabepilone 61 invasive bladder 61 intra arterial chemotherapy 61 carboplatin chemotherapy 61 Irinotecan 61 transvaginal sonography 61 Tavocept 61 ZACTIMA 61 thromboembolic disease 61 localized prostate cancer 61 Gemzar ® 61 dose melphalan 61 refractory metastatic 61 spinal metastases 61 metastatic liver 61 vinorelbine 61 decitabine 61 reperfusion therapy 61 undetectable HBV DNA 61 remission induction 61 leiomyomas 61 subgroup analyzes 61 gemcitabine cisplatin 61 differentiated thyroid 61 weekly subcutaneous injections 61 zoledronic acid 61 pemetrexed 61 angiographic restenosis 61 colorectal adenocarcinoma 61 K ras mutations 61 Kaplan Meier analysis 61 refractory AML 61 Trastuzumab 61 Cystectomy 61 metastatic malignant melanoma 61 hormonal therapies 61 genotypic resistance 61 Hurthle cell 61 FDG PET 61 Lumpectomy 61 pain palliation 61 elacytarabine 61 autologous hematopoietic stem cell 61 taxane chemotherapy 61 intracranial stenosis 61 systemic ALCL 61 angiographic outcomes 61 Fludara ® 61 hormone therapy estrogen 61 therapy IMRT 61 capecitabine Xeloda 61 carotid endarterectomy CEA 61 periprocedural 61 node metastases 61 cranial irradiation 61 ErbB2 positive 61 fibrinolytic therapy 61 fondaparinux 61 intensity modulated radiotherapy IMRT 61 cytotoxic chemotherapy 61 recurrent glioblastoma 61 VELCADE melphalan 61 assessing T DM1 61 standard chemotherapy regimen 61 GP IIb IIIa inhibitors 61 cetuximab Erbitux 61 Soft Tissue Sarcoma 61 FASLODEX 61 VTE prophylaxis 61 hyperplasia BPH 61 mapatumumab 61 colorectal carcinoma 61 HuMax EGFr 61 fluoropyrimidine 61 KRAS mutant tumors 61 tenofovir emtricitabine 61 eribulin 61 metastatic lesions 61 retroperitoneal 61 bone metastases 61 prostate cancer HRPC 61 liposomal doxorubicin 61 dose dexamethasone 61 idraparinux 61 Combination therapy 61 sunitinib malate 61 ARIMIDEX 61 androgen independent 61 ASCUS 61 custirsen 61 azacitidine 61 malignant ascites 61 RECIST Response Evaluation Criteria 61 EFAPROXYN 61 virologic failure 61 Flu Cy 61 ASCT 61 CsA 61 cilostazol 61 immunohistochemical staining 61 antiangiogenic agents 61 malignant lesions 61 undergone radical prostatectomy 61 TURBT 61 trabeculectomy 61 symptomatic fibroids 61 anthracycline chemotherapy 61 ATACAND 61 nodal metastasis 61 hepatocellular cancer 61 OPAXIO 61 autologous SCT 61 Hormone Refractory Prostate Cancer 61 Allovectin 7 ® 61 postoperative pulmonary 61 cinacalcet 61 bowel resection 61 endocrine therapy 61 DCVax ® Brain 61 prophylactic mastectomy 61 doxorubicin docetaxel 61 oral Hycamtin 61 ERBITUX Cetuximab 61 BRCA mutation carriers 61 Coronary Artery Bypass Graft 61 biologic DMARD 61 SUVmax 60 binary restenosis 60 symptomatic VTE 60 aldosterone antagonists 60 atherosclerotic renal artery stenosis 60 mg/m2 dose 60 uterine fibroid embolization 60 bladder prostate 60 abacavir lamivudine 60 para aortic 60 Alessandro Riva 60 PAOD 60 nodal dissection 60 PROCHYMAL 60 tamoxifen Nolvadex ® 60 dalteparin 60 sirolimus eluting stents 60 Ophena TM 60 docetaxel Taxotere 60 ibandronate 60 concomitant antibiotics 60 postoperative atrial fibrillation 60 CIMZIA TM 60 anastrazole 60 multimodality therapy 60 GISTs 60 unstable angina UA 60 bronchogenic carcinoma 60 FOLFIRI alone 60 EGFR mutation positive 60 Subgroup analyzes 60 duplex ultrasonography 60 Erlotinib 60 chemosensitivity 60 telaprevir dosed 60 oral anticoagulant therapy 60 intraoperative radiotherapy 60 extracolonic findings 60 methotrexate therapy 60 spontaneous bacterial peritonitis 60 NSABP B 60 GVAX 60 FUSILEV enhances 60 KRAS wild 60 β blockers 60 PCa 60 KRAS mutations 60 alteplase 60 cisplatin resistant 60 sorafenib tablets 60 preoperative staging 60 dosage regimens 60 lung resection 60 benign lesions 60 systemic corticosteroid 60 sentinel nodes 60 Stereotactic Body Radiation Therapy 60 Panzem R NCD 60 TLUS 60 doxorubicin cyclophosphamide 60 trabectedin 60 DMARD 60 ribavirin therapy 60 colon resection 60 lobular cancer 60 interferon alfa 2b 60 Adjuvant therapy 60 colorectal neoplasms 60 TRUS biopsy 60 fluorouracil 60 reinfarction 60 temozolomide TMZ 60 castrate resistant prostate cancer 60 H. pylori eradication 60 thromboembolic events 60 gefitinib 60 carcinoma HCC 60 Anthracycline 60 anastrozole 60 wedge resection 60 enzastaurin 60 OncoVEX GM CSF 60 mg kg dose 60 urethral bulking agent 60 prostatectomy 60 FOLFOX chemotherapy 60 invasive candidiasis 60 low dose cytarabine 60 fulvestrant 60 Lenalidomide 60 #.#ng/ml 60 abnormal mammogram 60 cervical carcinoma 60 ARB telmisartan 60 invasive carcinomas 60 5 Fluorouracil 60 pathologic examination 60 pulmonary metastases 60 ELOXATIN 60 MS relapses 60 subconjunctival injection 60 docetaxel 60 androgen ablation 60 PROSTVAC TM 60 specific antigen PSA 60 pelvic ultrasound 60 axitinib 60 AA Amyloidosis 60 RTOG 60 Rev Dex 60 RALP 60 Ophena 60 ImmuKnow 60 erlotinib Tarceva ® 60 MitraClip device 60 low dose Iluvien 60 mesalamine granules 60 dysplastic nevi 60 paclitaxel Taxol ® 60 CIMZIA TM certolizumab pegol 60 prostate biopsy 60 GnRH agonist 60 gefitinib Iressa 60 urothelial bladder cancer 60 mediastinoscopy 60 letrozole Femara 60 Surgical excision 60 thromboembolic complications 60 peg interferon 60 estramustine 60 OPCAB 60 intravesical infusion therapy 60 adenomatous 60 bladder carcinoma 60 HER2 positive 60 percutaneous drainage 60 mutated K ras 60 pre operatively 60 percutaneous vertebroplasty 60 metastatic renal cell 60 unresectable liver cancer 60 postmenopausal osteoporotic women 60 gastrectomy 60 refractory ovarian cancer 60 BR.# 60 TNF antagonist 60 mucosal healing 60 CaP 60 EXJADE 60 Cetuximab 60 endoscopic ultrasound 60 daunorubicin 60 Degarelix 60 adenoidectomy 60 pertuzumab 60 radiotherapy SBRT 60 AVODART 60 imatinib therapy 60 antifungal therapy 60 therapeutic regimens 60 prednisone prednisolone 60 Adjuvant Therapy 60 Percutaneous Coronary Intervention 60 neoadjuvant radiation 60 autologous transplant 60 Burch colposuspension 60 PREZISTA r 60 Folfox 60 idarubicin 60 cervical lymph node 60 DXA scan 60 salmeterol fluticasone 60 sleeve lobectomy 60 induce remission 60 velafermin 60 Intravenous CP 60 carotid artery stenosis 60 NSTE ACS 60 resections 60 extracranial 60 AGILECT R 60 VFEND 60 colon rectal 60 nonsquamous 60 prostate adenocarcinoma 60 tamsulosin 60 distant metastasis 60 antihypertensive therapy 60 ritonavir boosted 60 topotecan 60 gemcitabine 60 prospectively stratified 60 FOLFIRINOX 60 ovarian malignancy 60 Squamous 60 Temodar ® 60 sipuleucel T 60 chlorambucil 60 alkylating agent 60 antiretroviral naïve 60 abiraterone acetate 60 meniscectomy 60 HER2 amplified 60 untreated metastatic melanoma 60 neoplasias 60 Adjunctive 60 coinfected patients 60 Proxinium TM 60 VATS lobectomy 60 FFR guided 60 CR# vcMMAE 60 Mitoxantrone 60 vidofludimus 60 colorectal cancer CRC 60 BRIM2 60 PROLARIS 60 achieved ACR# 60 refractory colorectal cancer 60 Gemcitabine 60 intraductal 60 bendamustine 60 advanced neoplasia 60 chronic GVHD 59 bisphosphonate therapy 59 deCODE ProstateCancer TM 59 epidural steroid injections 59 HBeAg negative 59 situ CIS 59 focal cryoablation 59 B7 H3 59 intestinal metaplasia 59 orchidectomy 59 5 fluorouracil leucovorin 59 NovoTTF 59 Paraplatin ® 59 forodesine 59 cervical lesions 59 bevacizumab 59 postoperative AF 59 sarcomatoid 59 warfarin therapy 59 CIN3 59 glycoprotein IIb IIIa inhibitors 59 peginterferon 59 iniparib BSI 59 gadolinium enhanced 59 preoperative diagnosis 59 androgen deprivation therapy 59 DEXA scans 59 unfractionated heparin 59 APTIVUS R 59 nonmelanoma skin cancers 59 MACCE 59 guaiac 59 melanoma lesions 59 NEUVENGE 59 viral kinetics 59 Electronic Brachytherapy 59 chemopreventive agent 59 Localized Prostate Cancer 59 LAGB 59 Peginterferon 59 renal dysfunction 59 atypical ductal hyperplasia 59 thrombolytic therapy 59 cetuximab 59 Randomized trials 59 histologic subtype 59 trastuzumab Herceptin R 59 undergoing radical prostatectomy 59 hepatocellular carcinomas 59 neurologic progression 59 plus gemcitabine 59 trastuzumab Herceptin 59 nicardipine 59 stratifying patients 59 SCIg 59 urothelial cancer 59 carotid artery stenting 59 Breast conserving 59 cyclophosphamide chemotherapy 59 strontium ranelate 59 Digital Mammographic Imaging 59 Fludara 59 needle aspiration 59 TNF blocker therapy 59 photocoagulation 59 grade gliomas 59 chemotherapeutic regimens 59 echocardiographic parameters 59 Stage IIIb 59 pegylated liposomal doxorubicin PLD 59 adrenocortical cancer 59 Helicobacter pylori eradication 59 eptifibatide 59 Patients Treated With 59 virological failure 59 antiplatelet medications 59 DOXIL 59 prophylactic cranial irradiation 59 virologic response 59 thyroglobulin 59 NSCLC 59 allogeneic transplant 59 IRX 2 59 prolongs survival 59 evaluating T DM1 59 heavily pretreated 59 ovarian lung 59 transarterial 59 ritonavir boosted lopinavir 59 rt PA 59 intensity modulated radiotherapy 59 WBRT 59 recurrent DVT 59 Cyclophosphamide 59 IFN alfa 59 surgically resectable 59 liver biopsies 59 anticoagulant therapy 59 oral antidiabetic medication 59 Abciximab 59 paclitaxel Taxol 59 ablative therapy 59 Angiographic 59 pancreatic prostate 59 mucinous 59 ganetespib 59 colesevelam HCl 59 imetelstat 59 #mg BID [001] 59 clinicopathological features 59 antiarrhythmic drug 59 adefovir 59 Adjuvant Treatment 59 coronary CTA 59 posaconazole 59 oral anticoagulation 59 antireflux surgery 59 recurrent GBM patients 59 thrombolytic agents 59 autologous transplants 59 melphalan prednisone 59 pituitary adenomas 59 Thalomid ® 59 esophageal resection 59 lung metastasis 59 Metastatic Renal Cell Carcinoma 59 paroxysmal AF 59 mitoxantrone plus 59 endothelin antagonists 59 metachronous 59 immunosuppressive regimen 59 TAXUS Liberte Stent 59 stage IIIA 59 bone metastasis 59 DAPT 59 overlapping toxicities 59 hormone refractory 59 CIPN 59 autologous bone marrow 59 advanced epithelial ovarian 59 refractory CLL 59 transurethral 59 DEXA scan 59 pancreatic carcinoma 59 bone scintigraphy 59 metastases 59 tumor angiogenesis inhibitors 59 Mohs micrographic surgery 59 tirofiban 59 benign nodules 59 neutropenic patients 59 metastatic carcinoma 59 lung pancreatic